INCE Capital and Qiming Venture Partners led a USD50m Series B for Allorion Therapeutics, a China-based drug developer that focuses on treating oncology and autoimmune diseases, with participation from TF Capital, Long River Investment, 3SBio, Octagon Capital and Elikon Venture.